Zymeworks Priced, NYSE: ZYME

Early-stage biotech developing bispecific antibodies that target HER2 tumors.

Industry: Health Care

Latest Trade: $9.41 0.00 (0.0%)

First Day Return: 0.0%

Return from IPO: -27.6%

Industry: Health Care

Zymeworks' lead product candidate, ZW25, is a novel bispecific (dual-targeting) antibody currently being evaluated in an adaptive Phase 1 clinical trial, targeting two distinct domains of the human epidermal growth factor receptor 2, or HER2, a protein that promotes the growth of cancer cells. This unique design enables ZW25 to address patient populations with all levels of HER2 expression, including those with low to intermediate HER2-expressing tumors, who are otherwise limited to chemotherapy or hormone therapy. Approximately 81% of patients with HER2-expressing breast cancer and 57% of patients with HER2-expressing gastric and gastroesophageal junction cancer have tumors that express low to intermediate levels of HER2, making them ineligible for treatment with currently-approved HER2-targeted therapies, such as blockbuster drugs Herceptin and Perjeta. In the Phase 1 clinical trial, ZW25 has demonstrated preliminary anti-tumor activity across multiple cancer types in patients who have progressed after several lines of treatment with HER2-targeted therapies. Zymeworks' second product candidate, ZW33, is a bispecific antibody-drug conjugate, or ADC, based on the same antibody framework as ZW25 but armed with a cytotoxic (potent cancer cell-killing) payload. ZW33 is designed to target several indications characterized by HER2 expression; Phase 1 clinical trials are expected in the 2H17. It also has a pipeline of preclinical candidates and programs in immuno-oncology and other therapeutic areas. In addition, two of the therapeutic platforms have revenue-generating partnerships with Merck, Lilly, Celgene, GSK and Daiichi.
more less
IPO News for Zymeworks
more
IPO Data
IPO File Date 04/03/2017
Offer Price $13.00
Price Range $13.00 - $16.00
Offer Shares (mm) 4.5
Deal Size ($mm) $59
IPO Data
IPO Date 04/27/2017
Offer Price $13.00
Price Range $13.00 - $16.00
Offer Shares (mm) 4.5
Deal Size ($mm) $59
Underwriters
more
Company Data
Headquarters Vancouver, Canada
Founded 2003
Employees 136
Website www.zymeworks.com